Zeria Of Japan To Buy Tilotts Of Switzerland For $128 Million
This article was originally published in PharmAsia News
Executive Summary
Japan's Zeria Pharma said it plans to buy Tilotts Pharma of Switzerland for just over $128 million. Zeria reportedly made the purchase to expand its drug pipeline and widen its marketing ability abroad. Tilotts is attractive to Zeria because of its Asacol (mesalamine) drug for treating hypersensitive bowel syndrome. The product is considered a good fit with Zeria's gastrointestinal line of drugs. Zeria has been developing and marketing Asacol in Japan for the past five years. The purchase of Tilotts gives the Japanese company rights to sell the drug in 53 countries. (Click here for more - a subscription may be required